Medical materials

Publication
  • ASN •
  • 26 October, 2024 •
  • •

VALIANT: Phase 3 Trial of Pegcetacoplan for Patients With Native or Post-Transplant Recurrent C3G or Primary IC-MPGN

Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Li Li, Zhongshen Wang, Luis López Lázaro, Johan Szamosi, Fadi Fakhouri

Available materials

Oral Presentation
Publication
  • ASN •
  • 24 October, 2024 •
  • •

Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 52-week patient evolution

Anuja Java, Andrew S Bomback, David Kavanagh, Giuseppe Remuzzi, Gere Sunder-Plassmann, John Kanellis, Erica Daina, Patrick D. Walker, Zhongshen Wang, Zurish Ahmad, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 24 October, 2024 •
  • •

Long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: The long-term VALE extension study

Carla Nester, Gema Ariceta, Anwesha Mukherjee, Li Li, Johan Szamosi, Luis López Lázaro

Available materials

Poster
Publication
  • ASN •
  • 23 October, 2024 •
  • •

Efficacy and safety of SEL-212 in patients with refractory gout and chronic kidney disease: A post hoc analysis from the two Phase 3 DISSOLVE studies

Puja Khanna, Richard Johnson, Rehan Azeem, Aletta Falk, Bhavisha Desai, Hugues Santin-Janin, Herbert Baraf, Alan Kivitz

Available materials

Poster
Sign up for alerts